Literature DB >> 2776393

Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction.

R E Johnson1, E J Cone, J E Henningfield, P J Fudala.   

Abstract

A new, rapid dose-induction procedure was used in the evaluation of buprenorphine hydrochloride (buprenorphine) as a treatment for opiate dependence. Nineteen heroin-dependent men were given buprenorphine sublingually in ascending daily doses of 2, 4, and 8 mg and then maintained on 8 mg daily. The observations of the transition from heroin to buprenorphine for the first 4 days are described. During this period, subjects reported significantly elevated ratings of "good effects" and feelings of "overall well-being" and decreased ratings of "overall sickness." Data from subscales of the Addiction Research Center Inventory indicated increasing euphoria and decreasing dysphoria and sedation after buprenorphine administration. Subjects and observers consistently identified buprenorphine as an opiate and not as an opiate antagonist. These findings indicate that a rapid dose induction with buprenorphine is acceptable to heroin-dependent persons and that it causes minimal withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776393     DOI: 10.1038/clpt.1989.147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

2.  Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.

Authors:  Frank J Vocci; Robert P Schwartz; Monique E Wilson; Michael S Gordon; Timothy W Kinlock; Terrence T Fitzgerald; Kevin E O'Grady; Jerome H Jaffe
Journal:  Drug Alcohol Depend       Date:  2015-09-07       Impact factor: 4.492

3.  Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-12-09       Impact factor: 1.786

4.  Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.

Authors:  E C Strain; M L Stitzer; I A Liebson; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

5.  Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Robert A Whittington; Suzanne K Vosburg; William J Kowalczyk
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

6.  Controlled trial of maintenance treatment of intravenous buprenorphine dependence.

Authors:  J Ahmadi; K Ahmadi
Journal:  Ir J Med Sci       Date:  2003 Oct-Dec       Impact factor: 1.568

Review 7.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.